Dec. 2025 – New US patent further strengthens River Stone IP

River Stone Biotech have announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. This patent, covering the company’s uptake transporter technology, is the first grant of a new patent family and gives the company protection on its unique approach to bioconversion across a range of products.